NCT04008030 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID	NCT04008030
Title	A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC) (CheckMate 8HW)
Acronym	CheckMate 8HW
Recruitment	Active, not recruiting
Gender	both
Phase	Phase III
Variant Requirements	Yes
Sponsors	Bristol-Myers Squibb
Indications	colorectal cancer
Therapies	Nivolumab Fluorouracil + Irinotecan + Leucovorin Cetuximab Fluorouracil + Leucovorin + Oxaliplatin Bevacizumab Ipilimumab + Nivolumab
Age Groups:	senior \| adult
Covered Countries	USA \| TUR \| ROU \| NOR \| NLD \| ITA \| IRL \| GRC \| GBR \| FRA \| ESP \| DNK \| DEU \| CZE \| CAN \| BRA \| BEL \| AUT \| AUS \| ARG

Additional content available in CKB BOOST